Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Neuropathic pain is a global clinical problem; nevertheless, nerve injury treatment methods remain limited. Olanzapine has antinociceptive and anti-nueropathic properties; however, its preventive effects have not been assessed in nerve injury models.Methods: We prepared a partial sciatic nerve ligation (Seltzer model) or sham-operated model in male Sprague-Dawley rats under isoflurane anesthesia. In a pre-treatment study, we administered olanzapine (10 mg/kg) intraperitoneally 1 h before nerve ligation. In post-treatment and dose-dependent studies, we injected 3 different doses of olanzapine intraperitoneally 1 h after nerve ligation. Mechanical allodynia was measured before and 7 days after surgery. Immunohistochemical analysis using anti-Iba-1 antibody was used to assess the effect of olanzapine at the spinal level.Results: In the pre-treatment study, median withdrawal thresholds of the normal saline groups were significantly lower than those of the sham-operated groups; however, those of the olanzapine (10 mg/kg) and sham-operated groups were not different. In the post-treatment and dose-dependent studies, the median with-drawal thresholds of the olanzapine (2.5 mg/kg) and normal saline groups were not different; however, those of the olanzapine (10 and 50 mg/kg) groups were significantly higher than those of the normal saline groups. Olanzapine did not have a significant effect on the density of Iba-1 staining.Conclusions: Olanzapine attenuated mechanical allodynia dose-dependently in the Seltzer model. This anti-allodynic effect of olanzapine was observed even when injected 1 h after nerve ligation. This effect of olanzapine appeared to be unrelated to microglia activation in the ipsilateral dorsal horn of the lumbar spinal cord. (Korean J Pain 2015; 28: 185-192)
Abstract
Background: Neuropathic pain is a global clinical problem; nevertheless, nerve injury treatment methods remain limited. Olanzapine has antinociceptive and anti-nueropathic properties; however, its preventive effects have not been assessed in nerve injury models.Methods: We prepared a partial sciatic nerve ligation (Seltzer model) or sham-operated model in male Sprague-Dawley rats under isoflurane anesthesia. In a pre-treatment study, we administered olanzapine (10 mg/kg) intraperitoneally 1 h before nerve ligation. In post-treatment and dose-dependent studies, we injected 3 different doses of olanzapine intraperitoneally 1 h after nerve ligation. Mechanical allodynia was measured before and 7 days after surgery. Immunohistochemical analysis using anti-Iba-1 antibody was used to assess the effect of olanzapine at the spinal level.Results: In the pre-treatment study, median withdrawal thresholds of the normal saline groups were significantly lower than those of the sham-operated groups; however, those of the olanzapine (10 mg/kg) and sham-operated groups were not different. In the post-treatment and dose-dependent studies, the median with-drawal thresholds of the olanzapine (2.5 mg/kg) and normal saline groups were not different; however, those of the olanzapine (10 and 50 mg/kg) groups were significantly higher than those of the normal saline groups. Olanzapine did not have a significant effect on the density of Iba-1 staining.Conclusions: Olanzapine attenuated mechanical allodynia dose-dependently in the Seltzer model. This anti-allodynic effect of olanzapine was observed even when injected 1 h after nerve ligation. This effect of olanzapine appeared to be unrelated to microglia activation in the ipsilateral dorsal horn of the lumbar spinal cord. (Korean J Pain 2015; 28: 185-192)
참고문헌 (32)
- Yawn BP, "The prevalence of neuropathic pain : clinical evaluation compared with screening tools in a community population", Pain Med, 10, pp.586~593 (2009)
- Lecomte F, "Prevalence of neuropathic pain in emergency patients : an observational study", Am J Emerg Med, 29, pp.43~49 (2011)
- Johansen A, "Persistent postsurgical pain in a general population : prevalence and predictors in the Tromsø study", Pain, 153, pp.1390~1396 (2012)
- Jeong Beom Lee, "Effect of Perioperative Perineural Injection of Dexamethasone and Bupivacaine on a Rat Spared Nerve Injury Model", The Korean Journal of Pain, 23(3), pp.166~171 (2010), 대한통증학회
- 정기태, "The Effect of Urinary Trypsin Inhibitor Against Neuropathic Pain in Rat Models", The Korean Journal of Pain, 26(4), pp.356~360 (2013), 대한통증학회
- Taraneh Moini Zanjani, "The Attenuation of Pain Behavior and Serum COX-2 Concentration by Curcumin in a Rat Model of Neuropathic Pain", The Korean Journal of Pain, 27(3), pp.246~252 (2014), 대한통증학회
- Bymaster F, "Olanzapine : a basic science update", Br J Psychiatry Suppl, pp.36~40 (1999)
- Glazer WM., "Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality", J Clin Psychiatry, 61(3), pp.16~21 (2000)
- Schreiber S, "The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency", Pharmacol Biochem Behav, 64, pp.75~80 (1999)
- Kiser RS, "Olanzapine for the treatment of fibromyalgia symptoms", J Pain Symptom Manage, 22, pp.704~708 (2001)
- Khojainova N, "Olanzapine in the management of cancer pain", J Pain Symptom Manage, 23, pp.346~350 (2002)
- Silberstein SD, "Olanzapine in the treatment of refractory migraine and chronic daily headache", Headache, 42, pp.515~518 (2002)
- Gorski ED, "Report of three case studies with olanzapine for chronic pain", J Pain, 4, pp.166~168 (2003)
- Rico-Villademoros F, "Atypical antipsychotics in the treatment of fibromyalgia : a case series with olanzapine", Prog Neuropsychopharmacol Biol Psychiatry, 29, pp.161~164 (2005)
- Freedenfeld RN, "Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic.", Pain Pract, 6, pp.112~118 (2006)
- Torigoe K, "Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain", Anesthesiology, 116, pp.159~169 (2012)
- Tsuda M, "Neuropathic pain and spinal microglia : a big problem from molecules in"small"glia", Trends Neurosci, 28, pp.101~107 (2005)
- Ji RR, "p38 MAPK, microglial signaling, and neuropathic pain", Mol Pain, 3, pp.33~ (2007)
- Talbot S, "Key role for spinal dorsal horn microglial kinin B1 receptor in early diabetic pain neuropathy", J Neuroinflammation, 7, pp.36~ (2010)
- Chu YX, "Involvement of microglia and interleukin-18 in the induction of long-term potentiation of spinal nociceptive responses induced by tetanic sciatic stimulation", Neurosci Bull, 28, pp.49~60 (2012)
- Mika J, "Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain", Eur J Pharmacol, 623, pp.65~72 (2009)
- Seltzer Z, "A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury", Pain, 43, pp.205~218 (1990)
- Meyer JM, "From chlorpromazine to olanzapine : a brief history of antipsychotics", Psychiatr Serv, 48, pp.1137~1139 (1997)
- Wang HH, "Effect of D1 and D2 dopamine receptor antagonists on acupuncture analgesia", Sheng Li Xue Bao, 45, pp.61~68 (1993)
- Aravagiri M, "Pharmacokinetics and tissue distribution of olanzapine in rats", Biopharm Drug Dispos, 20, pp.369~377 (1999)
- Marx CE, "Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents", Neuropsychopharmacology, 28, pp.1~13 (2003)
- Djebaili M, "The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats.", J Neurotrauma, 22, pp.106~118 (2005)
- Meyer L, "Allopregnanolone prevents and suppresses oxaliplatinevoked painful neuropathy : multi-parametric assessment and direct evidence", Pain, 152, pp.170~181 (2011)
- Kawano T, "Role of the neurosteroid allopregnanolone in the hyperalgesic behavior induced by painful nerve injury in rats", J Anesth, 25, pp.942~945 (2011)
- Kuner R, "Central mechanisms of pathological pain", Nat Med, 16, pp.1258~1266 (2010)
- Zhang G, "Sensitive liquid chromatography tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue", J Chromatogr B Analyt Technol Biomed Life Sci, 858, pp.276~281 (2007)
- Maier C, "Quantitative sensory testing in the German Research Network on Neuropathic Pain(DFNS) : somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes", Pain, 150, pp.439~450 (2010)